139 related articles for article (PubMed ID: 15905711)
1. The case against using 5-aminosalicyclates in Crohn's disease: con.
Stange EF
Inflamm Bowel Dis; 2005 Jun; 11(6):613-5. PubMed ID: 15905711
[No Abstract] [Full Text] [Related]
2. The case for using 5-aminosalicyclates in Crohn's disease: pro.
Hanauer SB
Inflamm Bowel Dis; 2005 Jun; 11(6):609-12. PubMed ID: 15905710
[TBL] [Abstract][Full Text] [Related]
3. Mesalamine for prophylaxis of small bowel Crohn's disease recurrence.
Bauer WM; Brzezinski A; Lashner BA
Curr Gastroenterol Rep; 1999 Oct; 1(5):377-83. PubMed ID: 10980975
[TBL] [Abstract][Full Text] [Related]
4. Debate: should mesalamine be used in Crohn's disease?: comments and conclusions.
Kamm MA
Inflamm Bowel Dis; 2005 Jun; 11(6):616-7. PubMed ID: 15905712
[TBL] [Abstract][Full Text] [Related]
5. [Improved treatment of Crohn's disease].
Nau JY
Rev Med Suisse; 2005 May; 1(18):1241. PubMed ID: 15977716
[No Abstract] [Full Text] [Related]
6. Little benefit from mesalazine taken prophylactically after surgery for Crohn's disease.
Rutgeerts P
Gut; 2001 Apr; 48(4):452-3. PubMed ID: 11247886
[No Abstract] [Full Text] [Related]
7. 5-ASA therapy for active Crohn's disease: old friends, old data, and a new conclusion.
Feagan BG
Clin Gastroenterol Hepatol; 2004 May; 2(5):376-8. PubMed ID: 15118974
[No Abstract] [Full Text] [Related]
8. Mesalamine in the treatment of active Crohn's disease.
Dignass A; Marteau P
Gastroenterology; 2005 Jan; 128(1):245-6; author reply 246. PubMed ID: 15633152
[No Abstract] [Full Text] [Related]
9. Mesalamine maintenance therapy for Crohn's disease.
Feagan BG; McDonald JW
Gastroenterology; 2001 Feb; 120(2):585-6. PubMed ID: 11271451
[No Abstract] [Full Text] [Related]
10. Aminosalicylates for active disease and in the maintenance of remission in Crohn's disease.
Feagan BG
Eur J Surg; 1998 Dec; 164(12):903-9. PubMed ID: 10029385
[No Abstract] [Full Text] [Related]
11. Mesalamine derivatives in the treatment of Crohn's disease.
Harrell LE; Hanauer SB
Gastroenterol Clin North Am; 2004 Jun; 33(2):303-17, ix-x. PubMed ID: 15177540
[TBL] [Abstract][Full Text] [Related]
12. Mesalamine and relapse prevention in Crohn's disease.
Cottone M; Cammà C
Gastroenterology; 2000 Aug; 119(2):597. PubMed ID: 10960274
[No Abstract] [Full Text] [Related]
13. Mesalazine as a maintenance treatment in Crohn's disease.
Sutherland LR; Steinhart AH
Gut; 1998 Jan; 42(1):143-4. PubMed ID: 9505902
[No Abstract] [Full Text] [Related]
14. Efficacy of 5-aminosalicylates for the maintenance of remission in Crohn's disease.
Akobeng AK
Am J Gastroenterol; 2011 Oct; 106(10):1857; author reply 1857-8. PubMed ID: 21979212
[No Abstract] [Full Text] [Related]
15. 5-aminosalicylates to prevent relapse of Crohn's disease after surgery.
Doherty G; Moss AC
Am J Gastroenterol; 2012 Mar; 107(3):487; author reply 487-8. PubMed ID: 22388032
[No Abstract] [Full Text] [Related]
16. Obstructing Crohn's disease of the duodenum: is surgery always mandatory?
Karaoglu AO; Yukselen V
Int J Clin Pract; 2004 Feb; 58(2):221-3. PubMed ID: 15055874
[TBL] [Abstract][Full Text] [Related]
17. Aminosalicylates for induction of remission or response in Crohn's disease.
Lim WC; Hanauer S
Cochrane Database Syst Rev; 2010 Dec; (12):CD008870. PubMed ID: 21154400
[TBL] [Abstract][Full Text] [Related]
18. Aminosalicylates and Elderly-onset Colonic Crohn's Disease-More Than Meets the Eye?
Limdi JK
J Crohns Colitis; 2017 Aug; 11(8):1022. PubMed ID: 28333225
[No Abstract] [Full Text] [Related]
19. Presentation of Crohn's disease as metastatic cutaneous non-caseating granulomatous lesions.
Delgado J; Delgado B; Sztarkier I; Cagnano E; Sperber AD; Fich A
Isr Med Assoc J; 2003 Dec; 5(12):897-8. PubMed ID: 14689766
[No Abstract] [Full Text] [Related]
20. Budesonide led to a greater remission rate and fewer severe adverse events than did mesalamine in Crohn's disease.
Rutgeerts P
Gut; 1999 Jul; 45(1):13-4. PubMed ID: 10498451
[No Abstract] [Full Text] [Related]
[Next] [New Search]